Business
Faron to Present at Proactive Investors Forum
Faron to Present at Proactive Investors Forum.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \nRNS Number : 9624B Faron Pharmaceuticals Oy 22 June 2016 \n\nFaron Pharmaceuticals Ltd\n(\"Faron\" or the \"Company\")\n \nFaron to Present at the Proactive Investors One2One Forum on 22 June 2016\n \nTURKU - FINLAND 22 June 2016 - Faron Pharmaceuticals Ltd (LON: FARN), the clinical stage biopharmaceutical company, announces today that Markku Jalkanen, Chief Executive Officer, is scheduled to present at the Proactive Investors One2One Forum on Wednesday 22 June 2016 at 6:00pm in London.\nThe event will be held at Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, W1J 5EB from 6:00pm to 8:00pm, followed by a drinks reception.\nThis event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists.\nFurther information can found at: http://www.proactiveinvestors.co.uk/register/event_details/63 \n \nFor more information, please contact:\n \nFaron Pharmaceuticals Oy\nKatja Wallenlind\nPhone +358 (50) 577 4807\nE-mail: [email protected]\n \nHume Brophy, PR\nMary Clark, Eva Haas, Hollie Vile\nPhone: +44 207 862 6390\nE-mail: [email protected]\n \nCairn Financial Advisers LLP, Nominated Adviser\nEmma Earl, Tony Rawlinson and Rebecca Anderson \nPhone: +44 207 148 7900\n \nPanmure Gordon (UK) Limited, Joint Broker\nFreddy Crossley, Duncan Monteith (Corporate Finance)\nTom Salvesen (Corporate Broking)\nPhone: +44 207 886 2500\n \nWhitman Howard Limited, Nominated Broker\nRanald McGregor-Smith, Francis North\nPhone: +44 207 659 1234\n \nAbout Faron Pharmaceuticals Ltd\n \nFaron is a drug discovery and development company focused on creating novel treatments for medical conditions with significant unmet needs. The Company is based in Turku, Finland. The Company currently has a pipeline of clinical stage products focusing on acute organ traumas, cancer immunotherapy and vascular damage. The Company's lead candidate Traumakine®, has been developed to treat Acute Respiratory Distress Syndrome (\"ARDS\"), a rare, severe, life-threatening medical condition characterised by widespread inflammation in the lungs. Traumakine® is now in a pan-European pivotal Phase III study (INTEREST). Besides Traumakine®, Faron's pipeline consists of early stage assets incl...